BIOTECH CATALYST AI SCANNER — May WK2

The XBI has been coughing up gains all week, with macro-driven risk-off sentiment pressuring even names with clean data behind them. The notable pattern this issue: several large-cap biotech names — INSM, GPCR, RLAY, IDYA — are appearing in the scanner in deeply oversold territory, RSIs running in the 13–20 range after weeks of sector rotation. That kind of technical dislocation in well-capitalized companies is worth paying attention to, though it requires distinguishing between stocks that are oversold because the market misread a catalyst and stocks that are cheap because the narrative genuinely broke down.

Three PDUFAs cluster in the next 22 days: ACHV (June 20), MNKD (May 29), and CING (May 31). All three carry distinct risk profiles — a first-in-class smoking cessation agent with cash exceeding market cap, an inhaled pediatric insulin riding overbought momentum into its regulatory decision, and a reformulated stimulant making a comeback after years of dilutive setbacks. ASCO looms in early June and has already started pulling conference data into view, with IMMP, REPL, FENC, INSM, and BIVI all presenting within the next two weeks. The caliber of those presentations varies widely, and the write-ups below are explicit about which are pivotal readouts and which are conference data cuts.

On balance, this is an active window — multiple near-term binary events across the risk spectrum from sub-$15M micro-floats to $22B large-caps. If you're sizing positions, the featured write-ups below reflect that range.

What We're Tracking:

Trading Below Cash: ACHV, IMMP, BIVI, INAB
Cash Pressure: NTHI, REPL, BIVI, BMEA, CLRB, PSTV, RLAY, BCDA
Initial Data: NTHI, BIVI
Multi-Catalyst: None this week

FEATURED (#1–10)

#1. ACHV — Achieve Life Sciences Inc.

THE CATALYST Event: Cytisinicline (ORCA-3) — PDUFA in Smoking cessation of cigarettes Date: Jun 20, 2026 BSI: 8.35/10

A $354M private placement completed in April has pushed cash well beyond the $255M market cap — the FDA's award of a Commissioner's National Priority Voucher to cytisinicline signals it views this as a public health priority, not a niche cessation play. Achieve focuses exclusively on nicotine dependence, centered on cytisinicline, with Adare Pharma Solutions completing commercial manufacturing technology transfer ahead of a planned 2027 launch and Omnicom handling launch execution.

📈 The Setup: Cytisinicline is a synthetic analog of plant-derived cytisine that acts as a partial agonist at α4β2 nicotinic acetylcholine receptors (nAChRs — the primary receptor sites through which nicotine drives reward, craving, and dependence). By partially activating those receptors, it reduces withdrawal and blocks reinforcement from continued smoking. ORCA-2 Phase 3 (N=810 U.S. adults) met dual primaries: biochemically verified continuous abstinence weeks 9–12 hit 25.3% versus 4.1% for placebo on the 6-week regimen, and 32.6% versus 7.0% on the 12-week regimen. ORCA-3 replicated those outcomes and the data was published in JAMA Internal Medicine. The competitive angle against varenicline (Chantix, a dominant partial agonist) is real: nausea affected 7–9% of cytisinicline patients versus approximately 30% for Chantix — a tolerability gap that matters enormously in relapse-prone cessation therapy. The negative EV setup (cash exceeds cap) means the market is pricing in either a CRL or near-zero launch potential despite two clean Phase 3s.

✅ The Edge: Cytisinicline would be the first novel cessation agent approved in over 20 years, backed by two U.S. Phase 3 trials — something varenicline never had at its 2006 approval. The Commissioner's National Priority Voucher, granted to a small number of public-health-priority drugs annually, reduces the typical PDUFA review complexity.

⚠️ The Risk: Adare's commercial-scale manufacturing was just transferred from Achieve's prior CDMO, and an FDA pre-approval inspection of a newly transferred manufacturing process carries real uncertainty — the April sell-off was itself triggered by a manufacturing-related announcement. A CRL on CMC grounds would be the mechanism of failure here, not the clinical package.

#2. NTHI — NeOnc Technologies Holdings Inc.

THE CATALYST Event: NEO100-01 — Phase 2 Topline Data in Malignant recurrent WHO Grade 3/4 IDH1 Astrocytoma Date: May 2026 (Est.) BSI: 8.25/10

Enrollment in the pivotal Phase 2a trial completed November 2025, and the CEO purchased $300,000 in shares in April 2026 — the type of insider confirmation that the data window is live. The company's core technology is an intranasal delivery platform designed to bypass the blood-brain barrier (BBB — the highly selective membrane that prevents most systemic drugs from reaching the brain), and it has secured a $50M strategic partnership with Quazar Investment for MENA expansion plus a 30-site India alliance with CBCC Global Research.

📈 The Setup: Four months of runway and topline Phase 2 data due any day in May. This is maximum binary pressure. NEO100-01 is high-purity perillyl alcohol (a monoterpene that arrests the cell cycle, triggers apoptosis via Ras farnesylation inhibition, and reversibly permeates the blood-brain barrier) delivered intranasally — routing directly through the olfactory epithelium to reach the CNS without systemic exposure. In a 24-patient analyzed cohort (1 compassionate, 5 Phase 1, 18 Phase 2a), it produced 21% radiographic response rate by RANO criteria (Radiographic Assessment in Neuro-Oncology — the standard imaging-based tumor response standard) — well above the <8% typical for lomustine or bevacizumab salvage. Progression-free survival at 6 months (PFS6) hit 44% versus 21–31% historical norms. Vorasidenib (Servier) is approved for Grade 2 IDH1/2 gliomas but leaves the high-grade recurrent population without a targeted option. That's the market NTHI is targeting. That said: N=24, the trial design has limitations, and the regulatory pathway for intranasal delivery in this indication lacks FDA precedent. The BSI here reflects momentum and setup, not clinical certainty.

✅ The Edge: Intranasal administration is mechanistically differentiated — it sidesteps the BBB entirely rather than requiring systemic penetration, which is why neurotoxicity is absent at therapeutic concentrations. No other program is in Phase 2 for high-grade IDH1 recurrent astrocytoma with this delivery route.

⚠️ The Risk: The Phase 2a N=24 dataset is small, the trial design is investigator-led without a randomized control arm, and the FDA has historically required PFS or OS endpoints (not radiographic response alone) for accelerated approval in neuro-oncology. If topline data disappoints or the response rate narrows from the prior interim, four months of cash means dilution arrives immediately.

#3. IMMP — Immutep Limited

THE CATALYST Event: Eftilagimod Alpha with weekly paclitaxel (AIPAC-003) — Phase 2/3 Conference Presentation in Metastatic breast cancer (MBC) Date: May 30, 2026 FDA Status: FTD BSI: 7.74/10

Dr. Reddy's Laboratories licensed eftilagimod alpha rights for Asia and Greater China in January 2026 (US$20M upfront) — a deal that closed after TACTI-004's Phase 3 NSCLC failure, which itself cratered shares 80%. The willingness of a commercial partner to pay upfront after that failure says something about breast cancer optionality. Immutep is an Australian biotech (dual-listed ASX/Nasdaq) with MSD and Merck KGaA clinical supply deals and Novartis licensing its LAG525 program.

📈 The Setup: The market is penalizing AIPAC-003 for TACTI-004's sins — but the mechanisms of failure are not the same. TACTI-004 combined eftilagimod with pembrolizumab in NSCLC (PD-1 checkpoint blocker — a drug that removes the brakes on T cells), running into the problem that pembrolizumab already dominates that combination space. AIPAC-003 pairs eftilagimod with weekly paclitaxel in heavily pretreated HR+/HER2-neg/low metastatic breast cancer — a different IO/chemo synergy axis with different competitive dynamics. Eftilagimod alpha (efti) is a soluble LAG-3 protein that acts as an MHC class II agonist (a stimulant that activates antigen-presenting cells, the sentinels that prime the immune system to attack tumors), promoting dendritic cell maturation and T-cell priming. Phase 2 dose-optimization enrolled 66 patients (median 3 prior lines): at the 30mg optimal biological dose, ORR was 41.9% versus approximately 20% for capecitabine (standard salvage). ASCO May 30 will present translational biomarker data linking efti-driven lymphocyte activation to survival. The negative EV (cash exceeds cap by 2.4x) reflects maximal pessimism, which is the setup.

✅ The Edge: Efti's MHC class II agonism is mechanistically orthogonal to PD-1 blockade — it doesn't compete with pembrolizumab, it activates an upstream pathway. The Dr. Reddy's deal provides commercial validation in markets where the NSCLC failure is already priced in.

⚠️ The Risk: Phase 3 initiation can't start until the root-cause probe into TACTI-004's mechanism of failure is complete — that investigation extends into Q3 2026, meaning today's data is at ASCO but the next catalyst (Phase 3 go/no-go decision) is months away. APC agonism also lacks an established surrogate endpoint accepted by FDA for OS approval in chemo combinations.

#4. GPCR — Structure Therapeutics Inc.

THE CATALYST Event: ACCG-2671 — Phase 1 Conference Presentation in Obesity Date: Jun 07, 2026 BSI: 7.73/10

Aleniglipron Phase 2b data showing up to 15% placebo-adjusted weight loss preceded a $100M patent license agreement with Genentech covering GLP-1 assets in January 2026 — the kind of early institutional endorsement that validates the oral GLP-1 approach before Phase 3 data exists. A $747.5M public offering closed December 2025, and Phase 3 enrollment is targeted to begin in 2H2026. Structure is a San Francisco-based company focused entirely on oral small-molecule GPCR (G protein-coupled receptor — a class of cellular switch proteins that mediate hormone and metabolite signaling) modulators for metabolic disease.

📈 The Setup: Shares are down 29% in three weeks with RSI at 13.7 — historically the floor territory in GLP-1 sector rotation. $1.42B in cash funds operations past 2028, so there is no financing overhang. ACCG-2671 is an oral DACRA (dual amylin and calcitonin receptor agonist — activating the hormonal pathways that reduce appetite, slow gastric emptying, and boost energy expenditure) being developed as a fixed-dose combination partner for aleniglipron. In obese rodent models, ACCG-2671 demonstrated additive weight loss atop GLP-1 receptor agonism and outperformed cagrilintide (Novo Nordisk's injectable amylin analog, now in Phase 3 in the CagriSema combination). The ADA June 7 read-out is Phase 1 — first-in-human SAD/MAD (single ascending dose, then multiple ascending dose) safety and pharmacokinetics. This is not an efficacy readout; expect only safety, tolerability, and PK curve data. The question is whether ACCG-2671 can match aleniglipron's tolerability benchmark before advancing to combination studies.

✅ The Edge: ACCG-2671 is the only oral DACRA candidate in clinical development. Novo's CagriSema uses injectable peptides; a clean Phase 1 positions Structure as the only potential oral CagriSema analog — a meaningful differentiation in a market that has rewarded orals with premium valuations.

⚠️ The Risk: There is no human efficacy data behind ACCG-2671 at all. GI events are the known Achilles heel of amylin-class agents — pramlintide (Symlin, AstraZeneca/Bristol Myers) was withdrawn from meaningful use due to nausea and injection complexity; if the oral version carries similar tolerability issues, the combo rationale unravels before a combination trial can begin.

#5. FENC — Fennec Pharmaceuticals Inc.

THE CATALYST Event: STS-J01 — Phase 2/3 Conference Presentation in Non-metastatic solid tumors Date: Jun 01, 2026 BSI: 7.58/10

PEDMARK's positive topline STS-J01 results in Japan came in December 2025. Four ASCO 2026 abstracts were accepted for the June meeting. Fennec holds an exclusive license with Norgine Pharmaceuticals covering PEDMARQSI commercial rights in Europe, Australia, and New Zealand, and operates out of Research Triangle Park, North Carolina.

📈 The Setup: PEDMARK (sodium thiosulfate injection — an IV chemoprotectant administered 6 hours post-cisplatin that chelates toxic platinum metabolites, sparing the cochlear hair cells that convert sound to nerve signal) is the only approved pharmacologic otoprotectant on the market. There are no late-stage competitors pursuing cisplatin-induced hearing loss prevention. The U.S. pivotal Phase 3 (N=109) showed 39% ototoxicity incidence versus 68% with cisplatin alone — a statistically significant reduction without sacrificing tumor response rates. The Japan STS-J01 investigator-initiated single-arm trial met its primary endpoint (significant hearing loss reduction versus historical controls) and showed a 95% tumor overall response rate, replicating U.S. data on efficacy preservation. The June 1 ASCO presentation fills in the STS-J01 dataset ahead of a PMDA (Japan's equivalent of FDA) regulatory filing. This is a conference presentation of already-announced positive data — it expands the evidence base, it doesn't create new binary risk. 50% YoY U.S. PEDMARK sales growth into 2026 provides the commercial anchor.

✅ The Edge: First-mover without a competitor in ototoxicity prevention. Both the U.S. pivotal and STS-J01 Japan data show the same result — hearing protection without compromising tumor outcomes — which is the bar regulators want to see before approving in oncology support settings.

⚠️ The Risk: PMDA traditionally requires randomized data rather than single-arm historical comparisons. STS-J01's design (investigator-sponsored, single-arm) may draw a request for additional randomized study before PMDA approval, diverging from the FDA's path and extending the Japan timeline.

#6. MNKD — MannKind Corporation

THE CATALYST Event: Afrezza (Technosphere Insulin) (INHALE-1) — PDUFA Regulatory Decision in Pediatric type 1/2 diabetes Date: May 29, 2026 BSI: 7.51/10

Blackstone's $500M non-dilutive financing in August 2025 anchors a multi-revenue-stream business: Afrezza adult sales, Tyvaso DPI royalties (partnered with United Therapeutics for pulmonary arterial hypertension), and FUROSCIX (subcutaneous furosemide for heart failure edema, acquired via scPharmaceuticals in October 2025). Q1 2026 revenue reached $90M, up 15% year-over-year. MannKind develops inhaled drug delivery platforms from its Danbury, Connecticut base.

📈 The Setup: INHALE-1 (N=230, ages 4–17) tested Afrezza — Technosphere insulin inhalation powder, where porous microparticles enable rapid pulmonary absorption — against injected rapid-acting analogs (Humalog/lispro, NovoLog/aspart) plus basal insulin. The modified intent-to-treat (mITT) analysis met noninferiority with a between-group HbA1c difference of 0.37% against a prespecified 0.4% margin. The ITT missed (0.435%) because of a single non-adherent outlier. FEV1 (forced expiratory volume — the standard lung function metric) was stable throughout; severe hypoglycemia rates matched injectables. RSI at 73 says approval is already priced in. Afrezza would be the first needle-free mealtime insulin for the approximately 200,000 U.S. pediatric T1/T2 patients — a meaningful adherence argument in a population that strongly resists injections. The competitive position, however, is constrained: adult Afrezza has never captured more than a modest share of the adult market despite a decade of approval, and payer prior authorizations for pediatrics will be a real friction point.

✅ The Edge: No inhaled insulin competitor exists in pediatrics — Pfizer's Exubera was withdrawn in 2007 over commercial, not clinical, issues. A clean approval gives MannKind a new label for a device and formula already manufactured at scale.

⚠️ The Risk: FDA approved adult Afrezza with a required lung cancer warning following 4 post-marketing cases; pediatric application may prompt mandatory long-term FEV1 monitoring requirements. The ITT noninferiority miss also gives the agency a technical hook to demand additional confirmatory data before granting a broad pediatric label.

#7. INSM — Insmed Incorporated

THE CATALYST Event: ARIKAYCE (ENCORE) — NDA Filing Conference Presentation in Newly Diagnosed or Recurrent MAC Lung Disease Date: May 17, 2026 BSI: 7.43/10

ENCORE Phase 3b topline results came in March 23, 2026, supporting label expansion from refractory to frontline MAC lung disease (Mycobacterium avium complex — a slow-growing bacterial infection that colonizes lung tissue, particularly in patients with structural airway damage). Insmed holds commercial partnerships in Europe and Japan and acquired INS1148 (an anti-SCF monoclonal antibody) from Opsidio in December 2025 to diversify the respiratory pipeline. Operations are based in Bridgewater, New Jersey.

📈 The Setup: The stock is down 34% over three weeks while BRINSUPRI's commercialization ramp absorbs investor attention. That creates a setup worth examining: ARIKAYCE is the only FDA-approved treatment for MAC lung disease, currently limited to refractory cases (patients who fail 6+ months of standard multi-drug therapy). ENCORE's Phase 3b (N=425 newly diagnosed or recurrent patients) randomized ARIKAYCE against placebo on top of azithromycin-ethambutol (the standard-of-care backbone regimen for MAC-PD). The primary respiratory symptom score improved 17.8 versus 14.7 points at month 13 (p=0.0299). Six-month culture conversion — the rate at which sputum cultures turn negative, the functional marker of bacterial clearance — hit 87.8% versus 57.0% for standard care alone (p<0.0001). Standard care alone achieves 30–60% conversion in frontline MAC-PD. That 10x TAM expansion from refractory to frontline is not embedded in an RSI-19 chart. ARIKAYCE works by delivering amikacin (an aminoglycoside antibiotic) encapsulated in liposomes that fuse with alveolar macrophages (the lung immune cells where MAC bacteria hide intracellularly) — concentrating drug exactly where oral regimens cannot penetrate effectively.

✅ The Edge: No competing inhaled or targeted agent is late-stage for MAC lung disease. Frontline label expansion would make ARIKAYCE the standard of care for approximately 300,000 U.S. MAC-PD patients currently underserved by oral-only regimens.

⚠️ The Risk: Daily nebulization is a real-world barrier — higher discontinuations in ENCORE (14.6% versus 8.5% for placebo) driven by dysphonia, cough, and bronchospasm will be the frontline prescriber objection. KOLs familiar with the tolerability profile of oral azithromycin-ethambutol regimens will need compelling comparative arguments to add an inhaled agent to the front line.

#8. BIVI — BioVie Inc.

THE CATALYST Event: Bezisterim (NE3107) (SUNRISE-PD) — Phase 2 Conference Presentation in Parkinson's disease Date: May 17, 2026 BSI: 7.41/10

SUNRISE-PD enrollment completed January 2026, and the trial design shifted from adjunct to full monotherapy in early Parkinson's patients — a conceptually bolder move that tests the drug's standalone disease-modifying potential rather than its ability to boost levodopa. BioVie operates from Carson City, Nevada and is developing BIV201 (terlipressin) for ascites in advanced cirrhosis in parallel, seeking a Phase 3 partner for that program.

📈 The Setup: Cash exceeds market cap — this is a negative EV setup on $12M. Bezisterim (NE3107) is a blood-brain-barrier-penetrant oral small molecule that selectively inhibits ERK/NF-κB signaling to suppress TNF-α production (a cytokine — inflammatory messenger protein — that drives neuroinflammation in dopaminergic neurons). The theory is that targeting neuroinflammation addresses a driver of Parkinson's progression rather than just masking motor symptoms with dopamine replacement. Prior Phase 2a adjunct data showed 63.6% of NE3107+levodopa patients hit >30% MDS-UPDRS Part III (the standard clinician-rated motor symptom score) improvement at 2 hours post-dose. SUNRISE-PD (N=60) tests monotherapy in patients diagnosed less than 4 years prior. This is a conference presentation — not topline, not pivotal. AbbVie's tavapadon (a dopamine D1/D5 receptor agonist in Phase 3) and Roche's prasinezumab (an anti-alpha-synuclein antibody) are the well-funded competition. Bezisterim is earlier in mechanism validation than either.

✅ The Edge: Negative EV means the market is pricing in zero. Even trend-level monotherapy signal at a conference shifts the narrative from adjunct add-on (which every failed Parkinson's drug gets labeled) toward a standalone program with differentiated biology. The neuroinflammation target has no approved precedent — first signal here is genuinely first-in-class.

⚠️ The Risk: This is a Phase 2 conference presentation with N=60, hybrid decentralized design, and inconsistent MDS-UPDRS scoring risk across sites. ERK/NF-κB inhibition in Parkinson's has no FDA regulatory precedent; a positive read still faces a substantial pivotal trial requirement where BioVie would be outresourced by AbbVie's tavapadon program by a factor of 100.

#9. REPL — Replimune Group Inc.

THE CATALYST Event: RP2 with nivolumab — Phase 1 Conference Presentation in Advanced solid tumors Date: May 31, 2026 BSI: 7.39/10

RP1 received its second FDA complete response letter on April 10, citing manufacturing deficiencies — an outcome that triggered 63 initial layoffs and a full pipeline pivot toward RP2. The Bristol Myers Squibb clinical collaboration for nivolumab supply remains active. Replimune engineers potent HSV-1 (herpes simplex virus type 1, genetically modified to selectively infect and kill cancer cells while sparing normal tissue) oncolytic viruses and is based in Woburn, Massachusetts.

📈 The Setup: Replimune's stock is down 43.5% over three weeks and the company is pivoting on seven months of runway. RP2 is what's left — an armed HSV-1 chassis expressing GALV-GP R- (a fusogenic protein that induces bystander tumor cell death via cell-to-cell fusion), GM-CSF (a dendritic cell chemoattractant), and a tumor-localized anti-CTLA-4 fragment (an immune checkpoint inhibitor delivered directly to the tumor rather than systemically, which is how ipilimumab causes autoimmune toxicity at scale). Phase 1 (approximately 50 patients with advanced solid tumors) showed 33% ORR monotherapy (one complete response lasting 15+ months) and 29% ORR in a uveal melanoma expansion cohort. The nivolumab combination induced peripheral T-cell shifts without adding grade ≥3 immune-related adverse events (serious autoimmune reactions) beyond PD-1 monotherapy's baseline. T-VEC (talimogene laherparepvec, Amgen's approved oncolytic for melanoma) is the nearest approved comparator and lacks systemic reach in non-cutaneous tumors. This is a Phase 1 conference cut at ASCO — not a pivotal readout. Calibrate accordingly.

✅ The Edge: In uveal melanoma specifically, RP2+nivolumab reached the anti-PD-1-refractory population that tebentafusp (a T-cell-engaging bispecific, approved only for HLA-A*02:01 positive patients) cannot serve — roughly 50% of the already-small incident population. That's a real niche with no other active agent.

⚠️ The Risk: RP1's dual CRLs both cited viral potency consistency and CMC manufacturing deficiencies. FDA precedent now requires RP2 comparability data and manufacturing validation before any pivotal trial initiation — and that CMC work takes time that a seven-month runway doesn't easily support without dilution.

#10. CING — Cingulate Inc.

THE CATALYST Event: CTx-1301 (fixed dose, pediatric study) — PDUFA Regulatory Decision in ADHD Date: May 31, 2026 BSI: 7.33/10

Phase 3 success led directly to NDA filing and FDA acceptance in October 2025, ending years of dilutive financings that had defined the company's history. A $12M PIPE in February 2026 extended runway past PDUFA. Cingulate holds an exclusive manufacturing agreement with Bend Bio Sciences and a commercialization alliance with Indegene, and is based in Kansas City, Kansas.

📈 The Setup: What changed here is specific: Phase 3 worked, and worked cleanly. CTx-1301 deploys the Precision Timed Release (PTR) multi-layer tablet platform to deliver dexmethylphenidate HCl (d-MPH HCl — the active enantiomer of methylphenidate, the CNS stimulant that blocks dopamine and norepinephrine reuptake to reduce ADHD symptoms) across three timed pulses, achieving 12+ hours of plasma coverage and a controlled taper. The pivotal pediatric trial (N=103, ages 6–17, fixed doses 18.75/25/37.5 mg) met the primary ADHD-RS-5 (ADHD Rating Scale-5 — the validated clinician-administered symptom score) at all three doses (p<0.001; Cohen's d effect sizes 0.74–1.19) with efficacy persisting to 12 hours. The standard-of-care ceiling is approximately 8–10 hours for Focalin XR (dexmethylphenidate ER, generic) and Adderall XR (amphetamine mixed salts ER), both of which leave afternoon and evening homework hours unmanaged. CTx-1301 would be first to a May approval ahead of Otsuka's centanafadine (a non-dopaminergic stimulant, PDUFA July 2026), providing a prescriber-capture window.

✅ The Edge: The 505(b)(2) pathway uses dexmethylphenidate's established safety record to de-risk the regulatory submission — no novel safety signals required. All-day single-tablet coverage is a genuine unmet prescriber complaint in pediatric ADHD, where booster-dose management creates real compliance and scheduling friction.

⚠️ The Risk: FDA has historically scrutinized ADHD duration labeling when adult classroom studies conflict with pediatric pivotals — the N=21 adult PERMP (Permanent Product Measure of Performance, a validated attention test) study may draw label restriction questions. Even with a broad label, generic Focalin XR and Adderall XR cap pricing power, limiting the commercial ceiling without compelling head-to-head data.

WATCHLIST (#11–20)

#11. BMEA — Biomea Fusion Inc. [Metabolic / Type 2 Diabetes]

Price: $1.63 | Cap: $118M | Cash: $36M | RSI: 25.8 | Momentum: -11.9% Icovamenib (BMF-219) — Phase 2 Conference Presentation in Type 2 Diabetes (Jun 07, 2026) BSI: 7.20/10

The Intel: Icovamenib is an oral covalent Menin inhibitor (a small molecule that permanently binds the Menin protein to restore beta-cell proliferation and insulin secretion in type 2 diabetes) — a differentiated mechanism from GLP-1 receptor agonists (Ozempic/tirzepatide) that target appetite rather than beta-cell restoration. COVALENT-111 Phase 2 delivered up to 1.5% placebo-adjusted HbA1c reduction. The counterweight: 8 months of cash and a conference presentation, not topline — with GLP-1 agents now occupying the commercial category in a way that makes a new oral entrant a difficult commercial story even with clean data.

#12. IDYA — IDEAYA Biosciences Inc. [Oncology / Uveal Melanoma]

Price: $28.24 | Cap: $2.48B | Cash: $639M | RSI: 19.4 | Momentum: -8.9% Darovasertib with crizotinib (OptimUM-02) — Phase 2/3 Conference Presentation in 1L HLA*A2-negative metastatic uveal melanoma (May 29, 2026) BSI: 7.14/10

The Intel: RSI at 19.4 with $639M cash and a 26-month runway is a technical setup worth flagging, but the context matters: darovasertib (a PKC inhibitor — blocks a cancer-growth signaling protein) plus crizotinib (a MET inhibitor) showed 29% response rate in 1L HLA*A2-negative mUM, targeting the half of metastatic uveal melanoma patients ineligible for tebentafusp. The conference cut at ASCO May 29 will present the OptimUM-02 Phase 2/3 dataset; if response depth and durability hold, it's the only active 1L option for this patient subset.

#13. INAB — IN8bio Inc. [Oncology / Glioblastoma]

Price: $1.60 | Cap: $16M | Cash: $24M | RSI: 62.9 | Momentum: +11.9% INB-200 — Phase 1 Conference Presentation in Glioblastoma (Jun 01, 2026) BSI: 7.12/10

The Intel: Cash exceeds market cap (negative EV) for a GBM program with recent Phase 1 data showing 33% clinical benefit rate — in one of oncology's hardest indications. INB-200 is an allogeneic gamma-delta T cell therapy (donor-derived innate immune cells engineered for off-the-shelf tumor killing without patient tissue matching), administered IV without lymphodepletion (the chemotherapy conditioning typically required before cell therapies). Brain tumor penetration is the stated differentiator over other cell therapies. This is early Phase 1 with a micro float — speculative, but the valuation is minimal.

#14. WVE — Wave Life Sciences Ltd. [Respiratory / Alpha-1 Antitrypsin Deficiency]

Price: $7.24 | Cap: $1.39B | Cash: $519M | RSI: 45.4 | Momentum: +1.1% WVE-006 (RestorAATion-2) — Phase 1/2 Interim Data in AATD with homozygous PiZZ mutation (May 18, 2026) BSI: 6.99/10

The Intel: Wave is Singapore-domiciled with pending U.S. redomiciliation proposed for mid-2026 — a structural transition worth tracking. WVE-006 is an allele-selective RNA editor (a precision tool that corrects the faulty RNA message causing the disease without altering the DNA) targeting the PiZZ mutation in AATD (alpha-1 antitrypsin deficiency — a genetic condition causing progressive lung and liver damage). Interim RestorAATion-2 data May 18 will show functional AAT protein restoration levels following recent patient dosing. Vertex's inhaled trikafta approach and Arrowhead's ARO-AAT are comparators; Wave's editing mechanism is differentiated but pre-clinical proof-of-concept is still early in humans.

#15. CLRB — Cellectar Biosciences Inc. [Oncology / Waldenstrom's Macroglobulinemia]

Price: $3.30 | Cap: $14M | Cash: $7M | RSI: 61.2 | Momentum: +17.0% Iopofosine (CLR 131) (CLOVER-WaM) — Phase 2b Conference Presentation in Waldenstrom's macroglobulinemia (Jun 01, 2026) FDA Status: BTD BSI: 6.91/10

The Intel: BTD (Breakthrough Therapy Designation, which allows FDA to work closely with the developer and can accelerate review) with 41% response rate in prior interim data and five months of cash left. Iopofosine is a targeted radiotherapy — a phospholipid-drug conjugate that selectively delivers radiation to cancer cell membranes — treating relapsed/refractory WM (a rare B-cell lymphoma affecting plasma cells). BTD against MRD-negative responses puts it ahead of ibrutinib-refractory salvage options like venetoclax combinations, but the micro float (4.2M shares) and cash crunch make this a speculative position regardless of data quality.

#16. PSTV — PLUS THERAPEUTICS Inc. [Oncology / CNS Diagnostics]

Price: $5.95 | Cap: $41M | Cash: $15M | RSI: 45.3 | Momentum: +51.8% CNSide (FORESEE) — Phase 1 Conference Presentation in Leptomeningeal Metastases from Breast or NSCLC (May 17, 2026) BSI: 6.91/10

The Intel: CNSide is a blood-based assay detecting CNS circulating tumor cells (rare cancer cells shed into the bloodstream that signal metastatic spread into the cerebrospinal fluid lining), enabling non-invasive diagnosis of leptomeningeal metastases (LM — a devastating late-stage complication where cancer spreads to the membranes surrounding the brain and spinal cord). Prior data showed 97% sensitivity versus traditional CSF cytology. The differentiation from invasive lumbar puncture (spinal tap) is real, but this is a diagnostic companion program, not a therapeutic — commercial pathway and payer reimbursement model differ substantially from drug approvals. FORESEE conference May 17 presents real-world utility data.

#17. RLAY — Relay Therapeutics Inc. [Oncology / HR+ Breast Cancer]

Price: $12.51 | Cap: $2.40B | Cash: $183M | RSI: 18.0 | Momentum: -16.6% Zovegalisib + fulvestrant + ribociclib (ReDiscover-2) — Phase 3 Conference Presentation in PIK3CA-mutant HR+/HER2- Breast Cancer (May 20, 2026) FDA Status: BTD BSI: 6.91/10

The Intel: RSI at 18.0 on a $2.4B company with BTD is a striking dislocation — but 11 months of cash and a Phase 3 conference cut (not topline) drive the concern. Zovegalisib is a selective allosteric PI3Kα inhibitor (blocks the mutated PI3Kα protein driving tumor growth in PIK3CA-mutant tumors, more selectively than Novartis's Piqray/alpelisib, which causes hyperglycemia via wild-type PI3K inhibition). The triplet combination with fulvestrant and ribociclib (CDK4/6 inhibitor — a cell-cycle brake that works synergistically with hormone pathway targeting) showed 41% ORR in pretreated patients. Conference May 20 presents ReDiscover-2 data; a cash raise is likely regardless of outcome given 11-month runway.

#18. PVLA — Palvella Therapeutics Inc. [Dermatology / Vascular Malformations]

Price: $113.26 | Cap: $1.62B | Cash: $487M | RSI: 32.5 | Momentum: -13.0% QTORIN (TOIVA) — Phase 2 in Cutaneous venous malformations (May 20, 2026) FDA Status: FTD BSI: 6.82/10

The Intel: QTORIN is a topical mTOR inhibitor (a cream that locally suppresses the overactive cell growth pathway driving abnormal blood vessel formation) targeting cutaneous venous malformations — painful, disfiguring lesions with no approved pharmacologic treatment. Prior Phase 2 data showed 50%+ lesion reduction. FTD (Fast Track Designation) applies. The 135-month cash runway is real — Palvella is a fortress in a rare disease with no competing approved therapy, which makes the May 20 data read more confirmatory than binary. Modest float (14.3M shares) means reactions are amplified; downside is limited by cash.

#19. BDTX — Black Diamond Therapeutics Inc. [Oncology / GBM & NSCLC]

Price: $2.72 | Cap: $156M | Cash: $114M | RSI: 39.6 | Momentum: +5.4% Silevertinib (BDTX-1535) — Phase 2 in Glioblastoma and NSCLC (May 30, 2026) FDA Status: FTD BSI: 6.81/10

The Intel: Silevertinib is a brain-penetrant allosteric EGFR inhibitor (blocks the EGFR mutation driving tumor growth in GBM and NSCLC while sparing wild-type EGFR — healthy cells that other EGFR inhibitors like osimertinib damage, causing skin and GI toxicity). Prior Phase 1 data showed CNS responses. FTD in hand, 33-month runway, and the GBM EGFR-mutant space has no approved targeted agent — osimertinib (AstraZeneca's Tagrisso) is not brain-penetrant for the specific GBM EGFR variants. Phase 2 data May 30 will be the first real test of whether the CNS signal translates in a larger cohort.

#20. BCDA — BioCardia Inc. [Cardiovascular / Chronic Ischemia]

Price: $1.09 | Cap: $12M | Cash: -$1M | RSI: 37.8 | Momentum: -6.8% CardiAMP (BCDA-02) — Phase 3 Conference Presentation in Chronic Myocardial Ischemia (May 31, 2026) BSI: 6.76/10

The Intel: BioCardia has negative cash — this is a technically insolvent company presenting Phase 3 conference data in 23 days. CardiAMP (BCDA-02) is an autologous cardiopoietic cell therapy (a patient's own bone marrow stem cells selected via proprietary biomarkers for heart-repair potency, then catheter-delivered to ischemic tissue) targeting chronic myocardial ischemia patients who are no longer candidates for revascularization. The competitive field is pharmacotherapy and device management. Phase 3 conference May 31 needs to show compelling quality-of-life or perfusion data to attract financing that doesn't wipe out the current equity base. Maximum binary risk.

The Strategist's Take

This week's scanner reflects a broader sector dynamic that's worth naming directly: the market has become unusually bifurcated between deeply oversold large-caps and speculative micro-floats, with relatively little in the middle. INSM at a $22B cap, RSI 19.3, and ENCORE data showing 88% culture conversion in frontline MAC lung disease is the type of setup that typically corrects — not because the stock should trade 50% higher overnight, but because the frontline label expansion thesis has not been meaningfully priced in while the BRINSUPRI noise captures the headlines. IDYA and RLAY show similar patterns in the watchlist.

On the other end: NTHI, BIVI, and BCDA are all approaching near-zero cash with catalysts in the next 8–22 days. NTHI at BSI 8.25 represents the scanner's second-highest scoring name, but it's important to note that the high score is being driven by the technical setup (momentum, low float, proximity to catalyst) rather than fundamental certainty in the biology. The science and commercial viability signals are weak — this is a small N, investigator-led trial with an intranasal delivery mechanism that has no FDA precedent in glioma. The risk-adjusted thesis requires meaningful data on May's topline, not just a beat of the prior 21% radiographic response rate signal, to justify the $162M cap against $5M in cash.

The three PDUFAs — ACHV, MNKD, and CING — present three genuinely different risk profiles. ACHV is the most structurally compelling: the clinical package is clean, the negative EV setup is real, and the only failure mechanism is manufacturing inspection. CING is a legitimate comeback story with strong Phase 3 data and a defined competitive window over centanafadine. MNKD is the most technically precarious of the three — overbought at RSI 73 heading into a decision where the ITT missed and adult Afrezza's commercial history creates skepticism about pediatric uptake even on approval. Position sizing should reflect those distinctions.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.2 | Generated: 2026-05-08T09:37:48 | BSI +1.0 calibration applied